Research ArticleRadiopharmacy & Adjunctive Medications

Preclinical Assessment of 99mTc-Labeled Liposome Agents as an Effective Tracer in Nuclear Medicine

Anfal M. Alkandari, Medhat W. Shafaa and Yasser M. Alsayed
Journal of Nuclear Medicine Technology September 2020, 48 (3) 269-273; DOI: https://doi.org/10.2967/jnmt.119.239756

Article Figures & Data

Figures

Tables

  • TABLE 1

    Heart-to-Liver Ratio

    TimeLiposomeLiposome, nanocolloidPositive liposome, HSALiposome, HSA
    Early1.15 ± 0.3*1.08 ± 0.31.4 ± 0.21.01 ± 0.2†
    60 min0.72 ± 0.1‡0.78 ± 0.1*0.7 ± 0.2*0.76 ± 0.2†‡

    • ↵* P < 0.05 vs. liposome.

    • ↵† P < 0.05 vs. liposome HSA.

    • ↵‡ P < 0.01 vs. liposome HSA.

  • TABLE 2

    Heart-to-Kidney Ratio

    TimeLiposomeLiposome, nanocolloidPositive liposome, HSALiposome, HSA
    Early1.54 ± 0.50.77 ± 0.2*1.2 ± 0.10.74 ± 0.1†
    60 min1.08 ± 0.30.87 ± 0.30.87 ± 0.4*0.58 ± 0.09*†

    • ↵* P < 0.01 vs. liposome HSA.

    • ↵† P < 0.05 vs. liposome HSA.

  • TABLE 3

    Heart–to–Bone Marrow Ratio

    TimeLiposomeLiposome, nanocolloidPositive liposome, HSALiposome, HSA
    Early2.6 ± 0.82.07 ± 0.63.1 ± 0.5*1.85 ± 0.3
    60 (min)1.92 ± 0.61.8 ± 0.61.4 ± 0.41.56 ± 0.3*

    • ↵* P < 0.01 vs. liposome HSA.

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords